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ABSTRACT
Background: The heterogeneity of histological findings in preclinical diet-induced 
nonalcoholic fatty liver disease (NAFLD) animal models is highly challenging. Here, we 
aimed to evaluate the feasibility and stability of repeated liver biopsy in NAFLD animal 
models.
Methods: Heterogeneity of diet-induced NAFLD was evaluated at different time points in 52 
high-fat diet (HFD), 35 methionine choline-deficiency diet (MCD), and 166 western diet (WD) 
induced NAFLD mice. Serial liver biopsies (left lateral, right medial, and left medial lobes) 
were performed monthly for up to 3 months. Mortality rates and changes in food intake, 
body weight, and liver enzymes were assessed.
Results: At 12 weeks, of the HFD animals, 14% and 30% did not develop steatosis and lobular 
inflammation, respectively; of the MCD animals, 7% did not develop lobular inflammation; 
and of the WD animals, 14% and 51% did not develop steatosis and lobular inflammation, 
respectively. The mortality rate of repeated liver biopsy was 1.62% (2/123 mice died). 
Repeated liver biopsy can be used to trace disease progression. Although body weight, food 
intake, and liver enzymes slightly changed after biopsy, all recovered within a week. Repeated 
liver biopsy did not affect the degrees of inflammation and steatosis of the other liver lobes.
Conclusion: The diet-induced NAFLD models were quite heterogeneous. Our results suggest 
that the repeated liver biopsy before treatment was applicable and stable in this NAFLD 
animal study.
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INTRODUCTION
Nonalcoholic fatty liver disease (NAFLD) is common in adolescents as well as adults.1 The use 
of an animal model of NAFLD is critical to increasing our understanding of its pathogenesis. 
However, despite the proposal of many dietary animal models for NAFLD, none is perfect.2 
It is very well known that there is considerable heterogeneity among diet-induced NAFLD 
animal models. For example, it is common for some mice not to develop fatty liver after 12–16 
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weeks of a high-fat diet (HFD).3 However, the exact degree of heterogeneity in dietary NAFLD 
models remains largely unknown.
Ideally, the preclinical animal models should mimic a human clinical trial. Only biopsy-
proven NAFLD patients can be included in clinical trials. However, biopsy confirmation 
is not usually done in preclinical diet-induced NAFLD animal models. Moreover, baseline 
steatosis, inflammation, and fibrosis degrees should be similar in patients included in 
clinical trial. Baseline characteristics of conventional diet-induced NAFLD are usually 
unknown in diet-induced NAFLD animal models since histological confirmation of animal 
models and randomizations are not performed prior to such studies. Liver biopsy in 
NAFLD animal studies can apply inclusion and exclusion criteria (e.g., degrees of steatosis 
and inflammation). Histological assessment before active drug treatment is critical to the 
mimicking of a human clinical trial setting and improving study quality. Moreover, it allows 
for the evaluation of individual responses to treatment. Additionally, the animals should be 
stratified by disease severity. The development of a biopsy-confirmed NAFLD animal model is 
essential to reducing the uncertainty associated with animal studies.
Few recent studies have used biopsy-proven NAFLD animal models.4,5 However, there are 
no data about model feasibility and stability. The other strength of repeated liver biopsy is 
its ability to trace disease progression and identify new biomarkers for predicting treatment 
responses. To the best of our knowledge, the degrees of heterogeneity of diet-induced NAFLD 
models have never been studied on a large scale and the feasibility and stability of repeated 
liver biopsy models have never been evaluated.
Here we aimed to investigate the heterogeneity of disease severity in various diet-induced 
NAFLD animal models and demonstrate the feasibility and stability of repeated liver biopsy 
used therein.
METHODS
Variation in diet-induced NAFLD models
C57BL/6N mice (8 weeks old, male) were obtained from OrientBio (Seongnam, Korea). 
The mice were maintained in a temperature-controlled (23°C ± 2°C) and specific-pathogen-
free room under a 12 hours light/dark cycle. The histology of 52 HFD (60% kcal fat, 58Y1)-
induced NAFLD models was evaluated at 12 weeks (n = 44) and 18 weeks (n = 8). Thirty-five 
methionine choline-deficiency diet (MCD) (research diets, A02082002B)-induced NAFLD 
models were evaluated at 8 weeks (n = 6) and 12 weeks (n = 29). One hundred and sixty-six 
western diet (WD; Research Diets, D12079B)-induced NAFLD models were evaluated at 12 
weeks (n = 43) and 17 weeks (n = 123). Body weights were assessed weekly.
Repeated liver biopsy protocol
All surgical instruments were sterilized before the procedure. The mice were anesthetized with an 
intraperitoneal injection of Zoletil (Virbac Laboratories, Carros, France) and Rompun (Bayer Korea, 
Seoul, Korea). After being shaved, the abdominal site was disinfected using 10% iodine solution. 
An abdominal midline incision (< 1 cm long) was made and the liver was carefully exposed using 
a cotton swab. The obtained liver tissue biopsy specimens were < 3% of the total liver weight and 
about 0.9 cm long. Immediately thereafter, a heated spatula was applied to the biopsy site to 
arrest the bleeding (Fig. 1). The incision site was sutured with 5–0 synthetic absorbable braided 
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polyglycolic acid sutures. After surgery, the animals were kept warm under a heat lamp and treated 
with tetracycline in water as an antibiotic for 3 days. Repeated liver biopsies were performed three 
times during the 3 months of feeding. The liver biopsy sites included distal portions of the left 
lateral lobe (LLL), right medial lobe (RML), and left medial lobe (LML) (Figs. 1 and 2).
Histological analysis
For hematoxylin and eosin staining, biopsy specimens were fixed in 4% paraformaldehyde, 
paraffin-embedded, and sectioned (4 μm). Hematoxylin and eosin–stained liver samples and 
biopsy specimens were analyzed by a single pathologist, who graded the degrees of steatosis 
and lobular inflammation. Steatosis was scored as follows: < 5% (score 0); 5%–33% (score 1); 
> 33%–66% (score 2); > 66% (score 3). Lobular inflammation was graded as follows: no foci 
(score 0); < 2 foci/200× (score 1); 2–4 foci/200× (score 2); and > 4 foci/200× (score 3).
Feasibly and stability
Body weights and food intakes were measured weekly. Blood samples were collected 
immediately after the third biopsy and on days 2, 5, and 7 thereafter. Serum alanine 
aminotransferase and aspartate aminotransferase levels were assessed by an automated 
chemical analyzer (Hitachi–747; Hitachi, Tokyo, Japan).
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Fig. 1. Multiple liver Bx procedure. 
Bx = biopsy, LLL = left lateral lobe, RML = right medial lobe, LML = left medial lobe.
Statistical analysis
The measurements were independently repeated three times and the average values are 
expressed as mean ± standard deviation (SD). The statistical analysis was performed using 
SPSS version 18.0 for Windows (SPSS Inc., Chicago, IL, USA). One-way analysis of variance 
was performed to compare the means of the different values. P values < 0.05 were considered 
statistically significant.
Ethics statement
All of the experimental protocols were approved by The Hanyang Institutional Animal Care and 
Use Committee (HY-IACUC-16-0028, HY-IACUC-18-0013). All animals received humane care 
according to the criteria outlined in the “Guide for the Care and Use of Laboratory Animals.”
RESULTS
Histologic heterogeneity of diet-induced NAFLD
Degree of steatosis (grade 0, 14%; grade 1, 20%; grade 2, 20%; and grade 3, 45%) and 
inflammation (grade 0, 30%; grade 1, 52%; and grade 2, 18%) were quite diverse at 12 weeks 
in the HF group (Fig. 3). Both 8- and 12-weeks MCD diet–fed mice showed a higher steatosis 
grade than the HFD-fed mice. At 12 weeks, in the MCD group, the degrees of steatosis 
(grade 1, 21%; grade 2, 24%; and grade 3, 55%) and inflammation (grade 0, 7%; grade 1, 
24%; grade 2, 24%; and grade 3, 45%) were quite diverse. Likewise, at 12 weeks in the WD 
group, the degrees of steatosis (grade 0, 14%; grade 1, 12%; grade 2, 49%; and grade 3, 
26%) and inflammation (grade 0, 51%; grade 1, 23%; grade 2, 16%; and grade 3, 9%) were 
quite diverse. The 17-week WD-fed group also showed heterogeneous steatosis and lobular 
inflammation scores.
Stability of repeated liver biopsy
The biopsies were performed as shown in Fig. 1. For the repeat liver biopsy, we determined 
the liver fragment's mean size was 0.9 cm and the positions by frequency were LLL, RML, 
and LML (Figs. 1 and 2). The degrees of steatosis and hepatic inflammation progressed with 
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Fig. 2. Anatomic location of repeated liver Bx. 
RML = right medial lobe, LML = left medial lobe, LLL = left lateral lobe, RLL = right lateral lobe, Bx = biopsy.
time (Fig. 4). Overall, 123 mice underwent biopsy. Two mice died for a mortality rate of 1.62%. 
Nonalcoholic fatty liver activity score (NAS) was < 2 points in 27 (21.9%) of 123 WD mice. The 
serum alanine aminotransferase and aspartate aminotransferase levels were evaluated to assess 
liver damage after the third biopsy but had not increased in the normal chow (NC) and WD 
groups on days 2, 5, and 7 after biopsy (Fig. 5). Hepatic steatosis and inflammation increased 
with time. Although the mean body weight slightly decreased after biopsy, the difference was 
not statistically significant on a linear mixed-effects model (Fig. 5A). Body weight steadily 
increased during the experiment period showing statistically significant differences.
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Fig. 3. Variation of the diet-induced NAFLD model. (A, B) The heterogeneity of NAS score in a dietary NAFLD model. The steatosis score and lobular inflammation 
score evaluated by hematoxylin and eosin staining. HFD for 16 weeks (n = 44), HF for 18 weeks (n = 8). MCD for 8 weeks (n = 6), MCD for 12 weeks (n = 29). WD 
with fructose (55 g/L final concentration) for 12 weeks (n = 43), WD with fructose (55 g/L final concentration) for 17 weeks (n = 123). Steatosis score (grade: 0–3); 
lobular inflammation score (grade: 0–3). 
NAFLD = nonalcoholic fatty liver disease, NAS = nonalcoholic fatty liver disease activity score, NC = normal chow, HFD = high-fat diet 60%, MCD = methionine 
choline-deficient diet, WD = western diet.
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Fig. 4. Tracing disease progression using repeated liver Bx. (A) Timing of multiple liver biopsies. (B) Changes in 
intrahepatic fat accumulation and inflammation by time. 
Bx = biopsy, WD = western diet.
Tracking liver resection margin
Changes in biopsy resection margins were traced over time. The animals were sacrificed at 
2, 5, and 7 days as well as at 1 and 2 months after liver biopsy for evaluation of the changes 
in biopsy margins (Fig. 6). After 2 and 5 days, a necrotic area and inflammatory cells were 
observed in the biopsy resection margins. After 7 days, the inflammatory cell counts were 
reduced and fat was observed in the necrotic area. After 1 month, the necrotic area was 
decreased. After 2 months, the necrotic area and inflammation in the resection margins had 
disappeared completely.
Effects of repeated resection on other lobes
Next, we investigated whether liver resection or anesthesia could cause inflammation in the 
other liver lobes. After the liver resection, we performed an autopsy on the remaining four 
sites (LLL containing the first biopsy resection margin, portal vein side of the LLL, RML, 
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Fig. 5. Changes in body weight, food intake, and liver enzyme during repeated liver Bx. (A) Changes in body weight and food intake. (B) Changes in hepatic 
enzymes. 
Bx = biopsy, NC = normal chow, WD = western diet. 
aP < 0.05.
and LML) at 2, 5, and 7 days (Fig. 7A). The collected liver specimens for damage assessment 
included the following: first section, area of the first biopsy; second section, from the LLL 
containing the first biopsy resection margins; third section, from the portal vein part of the 
LLL, which is usually the site for liver sampling; fourth section, RML; and fifth section, LML. 
Repeated liver biopsy did not affect the degrees of inflammation and steatosis of the other 
liver lobes (Fig. 7B).
DISCUSSION
Heterogeneity in the histological findings was considerable in these diet-induced NAFLD 
models. Twenty percent of the diet-induced NAFLD models did not develop steatohepatitis 
(NAS ≤ 2 points). Thus, the use of repeated liver biopsy in this NAFLD animal model was 
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Fig. 6. Tracing changes of resection margins. (A) To trace resection margins, autopsies were performed on 
days 2, 5, and 7. (B) Hematoxylin and eosin staining was performed to determine that the hemorrhage caused 
by the heated spatula caused damage to the liver and then recovered. The arrow indicates inflammatory cells. 
Magnification: 50× and 400×. 
Bx = biopsy, WD = western diet, N = necrosis, INF = inflammatory cell.
feasible and stable. The overall mortality rate was 1.6%, and the changes in body weight, 
dietary intake, and liver enzymes were transient after the third liver biopsy.
A previous cohort showed that the NAFLD phenotypes vary quite widely among murine 
species.6-8 Around 30% of the animals did not develop sufficient hepatic inflammation and 
fibrosis.9 However, the exact percentages of NAFLD animal model failure and inadequacy 
remain largely unknown. In our study, we used three kinds of diet-induced NAFLD models. 
Heterogeneity in the histologic findings was lower in the MCD model than in the other 
models. Our findings were quite comparable to those of a previous report.10 Although the 
MCD model induced weight loss and did not cause insulin resistance, a key pathophysiologic 
risk factor for NAFLD,11 it is a very reproducible model. The WD model with enriched 
cholesterol and fructose showed more severe hepatic steatosis and hepatic inflammation 
than the HFD model in this study, but the heterogeneity of disease severity was considerable.
Our repeated biopsy model can mimic the clinical trial setting in NAFLD animal studies. 
The use of liver biopsy before the intervention can balance the basic characteristics between 
the control and active arms. Its use can involve the application of inclusion and exclusion 
criteria as in human clinical trials. Our data showed that 21.9% of the 17-week WD animal 
models had a NAS of < 2 points. Additionally, the use of liver biopsy before the intervention 
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Fig. 7. Intrahepatic inflammation of remnant liver during repeated liver Bx. (A) To assess the effects of repeated 
liver Bx on remnant disease liver, autopsies were performed on days 2, 5, and 7 to collect samples from five sites. (B) 
Hematoxylin and eosin staining showed that the inflammation score does not differ among the five remnant lobes. 
Bx = biopsy, WD = western diet, RM = resection margin, LLL = left lateral lobe, RML = right medial lobe, LML = left 
medial lobe.
can help with the identification of biomarkers to identify responders versus non-responders 
using the baseline liver tissue and serum samples. Human NAFLD shows a very heterogenous 
spectrum. Although many candidate chemicals has been applied in NAFLD, the resolution 
rate of nonalcoholic steatohepatitis was < 50%.12-16 Thus, it is very important to select 
subjects who are expected to have a good response. Although preclinical NAFLD animal 
models are homogenous entities compared to humans, not all animals respond to candidate 
chemicals. Metabolomic or RNA sequencing data from the pre-treatment liver tissue can 
be used to identify new biomarkers to predict good responders to candidate chemicals. 
Comprehensive data from pre-treated liver tissues facilitate our understanding of the mode 
of action and identify optimal target population. Metabolomic and (micro/long non-coding) 
RNA sequencing tests using pre-treatment liver tissue will facilitate the development of new 
prognostic biomarkers for certain target drugs. The use of liver biopsy before the intervention 
can help with following up on individual histological changes from the baseline point (pre) to 
the study end (post). Finally, a repeated liver biopsy can track the effects of the target drug.
Several investigators recently attempted to perform a biopsy to match the NAFLD severity 
in models between the experimental groups.4,7 However, a standard protocol for biopsy-
confirmed NAFLD model as well as its safety and reproducibility data were unavailable but 
necessary. To the best our knowledge, this is the first study to clarify the feasibly and stability 
of repeated liver biopsy. We suggested the exact biopsy site, sample size, and antibiotic use 
duration. Moreover, we also evaluated the possible unexpected effects of repeated biopsy on 
the other lobes. Although our protocol seemed generally safe, liver biopsy can cause transient 
inflammation, pain-induced starvation, or weight reductions in animal models. Thus, careful 
observation after liver tissue biopsy is necessary.
There were several limitations to this study. First, we used a short-term antibiotic duration. 
Antibiotic treatment can affect the microbiome and be a limitation for microbiota studies. 
Second, although we carefully investigated changes in intrahepatic inflammation in the 
remnant disease lobes (Fig. 6), sham-operated control group is also needed to investigate the 
safety of repeated liver biopsy and its effect on the remnant liver. Moreover, transaminase, 
bilirubin, and albumin levels are important. Unfortunately, we did not analyze changes 
in synthetic function (albumin and bilirubin). Third, various strains of mice contribute to 
an individual's susceptibility to developing hepatosteatosis. Although A/J mice showed 
insulin resistance and hypercholesterolemia during HFD treatment, glucose levels remained 
normal.17 BALB/c mice showed resistance to developing fatty liver and insulin resistance.18 
Thus, use of C57BL/6 strain mice is generally preferred because of their intrinsic predilection 
to develop steatosis under HFD treatment.19 C57BL/6J and C57BL/6N are the most widely 
used mice in animal studies. C57BL/6J mice showed the deletion of several functional genes 
(nicotinamide nucleotide transhydrogenase) and different patterns of single-nucleotide 
polymorphism compared to C57BL/6N mice.20 C57BL/6J mice showed moderately impaired 
glucose metabolism compared to C57BL/6N.21 We used BL/6N mice for all experimental 
periods. Thus, our findings might be limited to C57BL/6N mice. Further studies including 
various murine strains are needed to verify our findings.
Our findings suggest that this repeated liver biopsy model was applicable in this NAFLD 
animal study. Biopsy-proven NAFLD is clinically feasible and can be applied in preclinical 
drug testing studies.
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